IP Library Granted Patent US 7,888,314
Granted Patent B2
US 7,888,314 · App. 11/198,527 · Granted Feb 15, 2011

Compositions and methods for treating peripheral vascular disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,888,314
App. No.
11/198,527
Granted
Feb 15, 2011
Kind
B2
Abstract

The present invention relates to methods of treating intermittent claudication comprising administering glucagon-like peptide-1 (GLP-1) molecules to subjects suffering therefrom.

Claims (9)

1. A method of treating intermittent claudication in a subject comprising:

administering to a subject in need thereof a therapeutically effective amount of a molecule selected from the group consisting of GLP-1(1-37) (SEQ ID NO: 1), GLP-1(1-36)amide (SEQ ID NO: 2), GLP-1(7-37) (SEQ ID NO: 3), GLP-1(7-36)amide (SEQ ID NO: 4), exendin-3 (SEQ ID NO:7), exendin-4(SEQ ID NO:9) and a peptide sequence having greater than 90% sequence identity to any of SEQ ID NOs: 1-4; thereby treating intermittent claudication in the subject.

2. The method according to claim 1 wherein the molecule is selected from the group consisting of GLP-1(1-37) (SEQ ID NO: 1), GLP-1(7-36)amide (SEQ ID NO: 4), a peptide sequence having greater than 90% sequence identity to SEQ ID NO:1, and a peptide sequence having greater than 90% sequence identity to SEQ ID NO: 4.

3. The method according to claim 1 wherein the subject is also administered free radical scavengers.

4. The method according to claim 3 wherein the free radical scavenger is selected from the group consisting of glutathione, melatonin, Vitamin E, and superoxide dismutase.

5. The method according to claim 4 wherein the subject is also administered potassium.

6. The method according to claim 1 wherein the subject is also administered glucose.

7. The method according to claim 1 wherein the subject is human.

8. The method according the claim 1 wherein the molecule is administered by an infusion pump or by subcutaneous injection of a slow release formulation of the molecule.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Oct 1, 2012
From: ELI LILLY AND COMPANY
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 029057/0342 →
SECURITY AGREEMENT Recorded Nov 8, 2011
From: AMYLIN PHARMACEUTICALS, INC.
To: ELI LILLY AND COMPANY
Reel/Frame 027192/0334 →